Alyona A. Petukhova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alyona A. Petukhova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Sergey Yurievich Kopaev
S. Fyodorov Eye Microsurgery Federal State Institution
2 shared publications Копаев Сергей Юрьевич
Микрохирургия глаза имени академика С.Н. Фёдорова
2 shared publicationsПетухова Алена Алексеевна
Микрохирургия глаза имени академика С.Н. Фёдорова
2 shared publications- A. A. Panov
“Eximer” eye center; Academy of postgraduate education of the Federal Medical-Biological Agency
1 shared publication - Anatoly N. Bessarabov
Intersectoral Scientific and Technical Complex “Eye Microsurgery” named after Academician S.N. Fedorov
1 shared publication - Boris Dmitrievich Tsygankov
FSBEI HE Russian University of Medicine of the Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- Open Access
- 7 July 2026
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 23 (2) , 54-59
Initial experience of using of bifocal intraocular lens with high add power in patients with late stages of age-related macular degeneration
The aim of the study: To evaluate the clinical outcomes of implanting a high-add intraocular lens (IOL) Lentis MAX LS-313 MF80 in patients with late-stage age-related macular degeneration (AMD) and comorbid cataract. Research methodology: Two clinical cases were presented: patients with fibrovascular scar and geographic atrophy in macular zone who were undergone implantation of the Lentis MAX LS-313 MF80 IOL as part of a rehabilitation strategy for the better-seeing eye. A distinctive feature of this IOL is the presence of an additional near-vision segment on both anterior and posterior lens surfaces, providing an addition of +8,0 D. IOL power calculation was performed targeting emmetropia, with the addition segment oriented inferiorly during implantation. The main selection criterion for patients with fibrovascular scar in macular zone was the absence of intra- and subretinal fluid for at least 3 months. Preoperative diagnostics included standard clinical and functional examinations. In addition to standard clinical and functional examination, all patients were undergone optical coherence tomography (OCT) of the posterior segment and fundus photography to assess macular involvement. Postoperative evaluation of distance and near (33 cm) visual acuity was performed. The results of the research: No intra- or postoperative complications were observed. Both patients demonstrated improved visual function on the first postoperative day: uncorrected distance visual acuity was 0,1 and 0,2 in the first and second cases, respectively, and near visual acuity was 0,3 in both cases. Patients reported subjective improvement in near vision quality, the ability to read large print and perform daily tasks without additional correction. Conclusion: Implantation of the Lentis MAX LS-313 MF80 IOL is an effective and safe method for visual rehabilitation of patients with late-stage AMD. The absence of complications and functionally significant improvement in near vision confirm the feasibility of using this lens in patients with combined macular pathology and cataract. These results justify the need for further studies with a larger number of observations and long-term follow-up.
- 7 July 2026
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 23 (2) , 54-59
Open AccessInitial experience of using of bifocal intraocular lens with high add power in patients with late stages of age-related macular degeneration
The aim of the study: To evaluate the clinical outcomes of implanting a high-add intraocular lens (IOL) Lentis MAX LS-313 MF80 in patients with late-stage age-related macular degeneration (AMD) and comorbid cataract. Research methodology: Two clinical cases were presented: patients with fibrovascular scar and geographic atrophy in macular zone who were undergone implantation of the Lentis MAX LS-313 MF80 IOL as part of a rehabilitation strategy for the better-seeing eye. A distinctive feature of this IOL is the presence of an additional near-vision segment on both anterior and posterior lens surfaces, providing an addition of +8,0 D. IOL power calculation was performed targeting emmetropia, with the addition segment oriented inferiorly during implantation. The main selection criterion for patients with fibrovascular scar in macular zone was the absence of intra- and subretinal fluid for at least 3 months. Preoperative diagnostics included standard clinical and functional examinations. In addition to standard clinical and functional examination, all patients were undergone optical coherence tomography (OCT) of the posterior segment and fundus photography to assess macular involvement. Postoperative evaluation of distance and near (33 cm) visual acuity was performed. The results of the research: No intra- or postoperative complications were observed. Both patients demonstrated improved visual function on the first postoperative day: uncorrected distance visual acuity was 0,1 and 0,2 in the first and second cases, respectively, and near visual acuity was 0,3 in both cases. Patients reported subjective improvement in near vision quality, the ability to read large print and perform daily tasks without additional correction. Conclusion: Implantation of the Lentis MAX LS-313 MF80 IOL is an effective and safe method for visual rehabilitation of patients with late-stage AMD. The absence of complications and functionally significant improvement in near vision confirm the feasibility of using this lens in patients with combined macular pathology and cataract. These results justify the need for further studies with a larger number of observations and long-term follow-up.
- Open Access
- 23 October 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (3) , 49-54
Determination of structural features of eyes with high degrees of ametropia by the method of mathematical modeling
Purpose: Determination of the characteristics of the hypermetropic and myopic eye based on retrospective analysis, prospective study and mathematical modeling. Material and methods: In the course of a retrospective study 2 groups were formed: group 1 – “High degree hyperopia”, anterior-posterior length (APL) of the eye less than 22 mm (n = 20543 eyes), group 2 – “High degree myopia”, APL of the eye more than 27 mm (n = 16718 eyes). The following data were obtained from the electronic database of medical records: visometry – uncorrected visual acuity (UCVA) and corrected visual acuity (CVA), autorefractometry data, tonometry, optical biometry of the eye, optical coherence tomography, optical power of the IOL, accompanying surgical interventions. During the prospective study 2 groups were formed: Group 1 – 35 eyes with axial length from 15.41 mm to 22.29 mm, Group 2 – 34 eyes with axial length from 27.13 to 33.39 mm. Conclusion: The calculations revealed differences characteristic of high-degree hyperopia and myopia. Using the results of additional diagnostic methods, models of eyes with high-degree hyperopia and myopia were constructed, taking into account anatomical features.
- 23 October 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (3) , 49-54
Open AccessDetermination of structural features of eyes with high degrees of ametropia by the method of mathematical modeling
Purpose: Determination of the characteristics of the hypermetropic and myopic eye based on retrospective analysis, prospective study and mathematical modeling. Material and methods: In the course of a retrospective study 2 groups were formed: group 1 – “High degree hyperopia”, anterior-posterior length (APL) of the eye less than 22 mm (n = 20543 eyes), group 2 – “High degree myopia”, APL of the eye more than 27 mm (n = 16718 eyes). The following data were obtained from the electronic database of medical records: visometry – uncorrected visual acuity (UCVA) and corrected visual acuity (CVA), autorefractometry data, tonometry, optical biometry of the eye, optical coherence tomography, optical power of the IOL, accompanying surgical interventions. During the prospective study 2 groups were formed: Group 1 – 35 eyes with axial length from 15.41 mm to 22.29 mm, Group 2 – 34 eyes with axial length from 27.13 to 33.39 mm. Conclusion: The calculations revealed differences characteristic of high-degree hyperopia and myopia. Using the results of additional diagnostic methods, models of eyes with high-degree hyperopia and myopia were constructed, taking into account anatomical features.
- 30 September 2024
- Published by LLC Science and Innovations in Saratov Journal of Medical Scientific Research
- Vol. 20 (3) , 255-258
Surgical treatment of paralytic mydriasis caused by belladonna preparation intake (a clinical case)
This rare clinical case demonstrates the treatment of paralytic mydriasis caused by taking a herbal drug, Atropa belladonna, which is extremely rare in the treatment of diseases today, using sequential implantation of an intraocular lens (IOL) and an artificial iris with simultaneous correction of refractive errors. The patient took Atropa belladonna extract for 5 years to prevent exacerbation of gastric ulcer according to the scheme 2 times a year (spring, autumn) for 2 weeks, 5-7 drops 3 times a day with meals. The uniqueness is explained by the fact that paralytic mydriasis arose as a result of long-term drug exposure. Analysis of the state of the iris stroma showed the impossibility of performing suture plasty of the pupil. In addition, patients with this pathology have been denied treatment in other medical institutions for decades.
- 30 September 2024
- Published by LLC Science and Innovations in Saratov Journal of Medical Scientific Research
- Vol. 20 (3) , 255-258
Surgical treatment of paralytic mydriasis caused by belladonna preparation intake (a clinical case)
This rare clinical case demonstrates the treatment of paralytic mydriasis caused by taking a herbal drug, Atropa belladonna, which is extremely rare in the treatment of diseases today, using sequential implantation of an intraocular lens (IOL) and an artificial iris with simultaneous correction of refractive errors. The patient took Atropa belladonna extract for 5 years to prevent exacerbation of gastric ulcer according to the scheme 2 times a year (spring, autumn) for 2 weeks, 5-7 drops 3 times a day with meals. The uniqueness is explained by the fact that paralytic mydriasis arose as a result of long-term drug exposure. Analysis of the state of the iris stroma showed the impossibility of performing suture plasty of the pupil. In addition, patients with this pathology have been denied treatment in other medical institutions for decades.
- Open Access
- 4 January 2022
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 14 (4) , 172-178
Adverse ocular effects of neuroleptic therapy: semiotics, pathogenesis and treatment
Antipsychotics are widely used in psychiatric practice for treating schizophrenia, bipolar disorder, and other diseases, including those treated off-label. They manifest many adverse effects, including ophthalmic ones. Some of these effects, such as persistent mydriasis, cycloplegia, extraocular muscle dystonia, and visual hypersensitivity attacks are reversible, since they disappear after dose reduction or drug withdrawal. Yet other side effects, such as cataracts, corneal edema, acute angle closure glaucoma and retinopathy are threatening for sight and may lead to permanent visual acuity decline and even blindness. The review provides data on the incidence of ocular side effects (both typical and atypical) of multiple antipsychotics, their clinical manifestations, pathogenesis and treatment. Eye examination is recommended for patients taking antipsychotics in the early periods of treatment and then twice a year. The psychiatrists need to know about the adverse effects of individual drugs whilst the ophthalmologists should be aware of their semiotics, pathogenesis and treatment, since timely diagnosis and treatment of pathological changes, together with antipsychotic therapy modification, prevent the development of severe and irreversible visual impairment in the majority of cases.
- 4 January 2022
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 14 (4) , 172-178
Open AccessAdverse ocular effects of neuroleptic therapy: semiotics, pathogenesis and treatment
Antipsychotics are widely used in psychiatric practice for treating schizophrenia, bipolar disorder, and other diseases, including those treated off-label. They manifest many adverse effects, including ophthalmic ones. Some of these effects, such as persistent mydriasis, cycloplegia, extraocular muscle dystonia, and visual hypersensitivity attacks are reversible, since they disappear after dose reduction or drug withdrawal. Yet other side effects, such as cataracts, corneal edema, acute angle closure glaucoma and retinopathy are threatening for sight and may lead to permanent visual acuity decline and even blindness. The review provides data on the incidence of ocular side effects (both typical and atypical) of multiple antipsychotics, their clinical manifestations, pathogenesis and treatment. Eye examination is recommended for patients taking antipsychotics in the early periods of treatment and then twice a year. The psychiatrists need to know about the adverse effects of individual drugs whilst the ophthalmologists should be aware of their semiotics, pathogenesis and treatment, since timely diagnosis and treatment of pathological changes, together with antipsychotic therapy modification, prevent the development of severe and irreversible visual impairment in the majority of cases.